Dermata Therapeutics, Inc. is a late-stage medical dermatology company. Co. is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, DMT310, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a U.S. market size of approximately 50 million patients. We show 13 historical shares outstanding datapoints in our coverage of DRMA's shares outstanding history.
Understanding the changing numbers of DRMA shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like DRMA versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching DRMA by allowing them to research DRMA shares outstanding history
as well as any other stock in our coverage universe. |
Free DRMA Email Alerts:
Video: Shares Outstanding Importance
